Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

SLN ("Silence" or the "Company"), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, ...

Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”) (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering ...

Fintel reports that on March 3, 2025, Leerink Partners downgraded their outlook for Pliant Therapeutics (NasdaqGS:PLRX) from ...

In a report released on March 2, David Risinger from Leerink Partners maintained a Hold rating on Amgen (AMGN – Research Report). The company’s ...

Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price dropped by Leerink Partners from $7.00 to ...

A live audio webcast of the fireside chat can be accessed through the Investors section of the Company’s website at www.mereobiopharma.com/investors. An archived replay of the webcast will be ...

Over the last decade, as the Institute for Clinical and Economic Review (ICER) has estimated the cost-effectiveness of newly approved drugs—and often declared them overpriced—companies in the indus | ...

today announced that management is scheduled to present at the 2025 Leerink Partners Global Healthcare Conference on Tuesday, March 11 th at 3:00 p.m. ET. An audio webcast of the presentation can ...

(“Innate” or the “Company”) today announced that members of its executive team will present and host 1x1 meetings at the Leerink Partners 2025 Global Healthcare Conference being held on ...

AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside chat at 7:40 a.m. Central time.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) was downgraded by research analysts at Leerink Partners from an “outperform” rating to a “market perform” rating in a report released on Monday, ...